Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

More is less—combining targeted therapies in metastatic colorectal cancer

Nature Reviews Clinical Oncology volume 6, pages 731–733 (2009)Cite this article

Abstract

Targeted agents directed at VEGF, such as bevacizumab, and EGFR, such as cetuximab and panitumumab, have become part of the standard treatment of metastatic colorectal cancer. Only a subset of patients seem to benefit from such treatment, and varying results have been observed when different lines of treatment are used in combination with different cytotoxic drugs. Preclinical and early clinical data have shown promising results for the combination of anti-VEGF and anti-EGFR treatment. However, two recent phase III trials, CAIRO2 and PACCE, have shown a detrimental effect of adding an anti-EGFR antibody to standard chemotherapy plus bevacizumab. We discuss issues that may explain these unexpected results.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).

    Article  CAS  Google Scholar 

  2. Kabbinavar, F. F. et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 23, 3706–3712 (2005).

    Article  CAS  Google Scholar 

  3. Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J. Clin. Oncol. 25, 1539–1544 (2007).

    Article  CAS  Google Scholar 

  4. Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013–2019 (2008).

    Article  CAS  Google Scholar 

  5. Sobrero, A. F. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2311–2319 (2008).

    Article  CAS  Google Scholar 

  6. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408–1417 (2009).

    Article  CAS  Google Scholar 

  7. Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671 (2009).

    Article  CAS  Google Scholar 

  8. Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626–1634 (2008).

    Article  CAS  Google Scholar 

  9. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).

    Article  CAS  Google Scholar 

  10. Lievre, A. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374–379 (2008).

    Article  CAS  Google Scholar 

  11. Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705–5712 (2008).

    Article  CAS  Google Scholar 

  12. Tol, J. et al. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98–99 (2009).

    Article  CAS  Google Scholar 

  13. Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563–572 (2009).

    Article  CAS  Google Scholar 

  14. Ciardiello, F. et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6, 3739–3747 (2000).

    CAS  PubMed  Google Scholar 

  15. Tonra, J. R. et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 12, 2197–2207 (2006).

    Article  CAS  Google Scholar 

  16. Saltz, L. B. et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25, 4557–4561 (2007).

    Article  CAS  Google Scholar 

  17. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).

    Article  CAS  Google Scholar 

  18. Hecht, J. R. et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672–680 (2009).

    Article  CAS  Google Scholar 

  19. Tol, J. et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann. Oncol. 19, 734–738 (2008).

    Article  CAS  Google Scholar 

  20. Antonacopoulou, A. G. et al. EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology 53, 698–706 (2008).

    Article  CAS  Google Scholar 

  21. Duff, S. E. et al. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur. J. Cancer 42, 112–117 (2006).

    Article  CAS  Google Scholar 

  22. Scartozzi, M. et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann. Oncol. 20, 227–230 (2009).

    Article  CAS  Google Scholar 

  23. Allain, P. et al. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab. Dispos. 28, 1379–1384 (2000).

    CAS  PubMed  Google Scholar 

  24. Bukowski, R. M. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25, 4536–4541 (2007).

    Article  CAS  Google Scholar 

  25. Cohen, E. E. et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 10, 247–257 (2009).

    Article  CAS  Google Scholar 

  26. Dickler, M. N. et al. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin. Cancer Res. 14, 7878–7883 (2008).

    Article  CAS  Google Scholar 

  27. Ince, W. L. et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl Cancer Inst. 97, 981–989 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

    Cornelis J. A. Punt & Jolien Tol

Authors
  1. Cornelis J. A. Punt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jolien Tol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cornelis J. A. Punt.

Ethics declarations

Competing interests

C. J. A. Punt is on the speakers' bureau for Roche and receives grant/research support from Merck Serono, Pfizer and Roche. J. Tol declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Punt, C., Tol, J. More is less—combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 6, 731–733 (2009). https://doi.org/10.1038/nrclinonc.2009.168

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.168

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing